Biohaven enrolls first patient in phase 3 Spinocerebellar Ataxia clinical trial of Troriluzole

02:52 EDT 18 Mar 2019 | Pharmaceutical Business Review

Hereditary Spinocerebellar Ataxias are rare, potentially fatal neurodegenerative disorders affecting the cerebellum. They are characterized clinically by progressive ataxia symptoms, including difficulties with balance, speech, and coordination, and

More From BioPortfolio on "Biohaven enrolls first patient in phase 3 Spinocerebellar Ataxia clinical trial of Troriluzole"